



Manhattan Pharmaceuticals To Present At 2nd Annual Obesity Drug Development Summit

NEW YORK, NY JULY 19 - Manhattan Pharmaceuticals, Inc. (AMEX: MHA) today announced that Alan G. Harris, MD, PhD, chief medical officer, will present a scientific overview of oral Oleoyl-estrone (OE), the company's product candidate in development for the treatment of obesity, at the 2nd Annual Obesity Drug Development Summit. The summit is being held July 27-28, 2006 at the Ritz-Carlton in Tyson's Corner, VA; Dr. Harris' presentation will take place on Thursday, July 27 from 10:10am - 10:40am EDT. OE is currently being tested in a Phase IIa clinical trial in Switzerland.

About Manhattan Pharmaceuticals, Inc.

Manhattan Pharmaceuticals, Inc., a development-stage pharmaceutical company, acquires and develops proprietary prescription drugs for large, underserved patient populations. In view of the worldwide obesity epidemic, the company is developing OE, an orally administered novel therapeutic for the treatment of obesity. To meet the needs of other major, underserved medical markets while lowering development risks, Manhattan Pharmaceuticals is also developing PTH (1-34), a peptide believed to be a regulator of epidermal cell growth, for psoriasis, and Propofol Lingual Spray, a convenient, proprietary lingual spray formulation of propofol, the world's best-selling general anesthetic, as a sedative-hypnotic for use during diagnostic and therapeutic procedures. (<http://www.manhattanpharma.com>)